eviQ proven-CNS R-CODOX-M / R-IVAC reference for specialist review

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	None declared

ID	`REG-CODOX-IVAC-PROVEN-CNS`
Type	Regimen
Status	pending_clinical_signoff
Diseases	None declared
Sources	`SRC-EVIQ-BURKITT-CNS-CODOX-4492` `SRC-EVIQ-BURKITT-CNS-IVAC-4493` `SRC-EVIQ-CNS-CODOX-PATIENT-4492` `SRC-EVIQ-CNS-IVAC-PATIENT-4493` `SRC-EVIQ-MOUTH-PATIENT-3099`

Notes

Explicit eviQ 4492 v1/4493 v2 proven-CNS reference, not a merged trial calendar or individualized prescription. IVAC rituximab days 3/7 are a committee adaptation from a trial excluding CNS disease; this is not randomized proven-CNS efficacy evidence. The 16 IT treatments here differ from the Phillips 2020 trial prose (eight standard plus four additional). Eligibility, age/fitness, immune/HIV context, organ function and toxicity require specialist review. No efficacy or reimbursement claim is supplied. NEVER give vincristine intrathecally.

Used By

Indication

IND-BURKITT-1L-CODOX-IVAC-PROVEN-CNS - IND-BURKITT-1L-CODOX-IVAC-PROVEN-CNS

Monitoring

MON-CODOX-IVAC-PROVEN-CNS - eviQ proven-CNS CODOX-M / IVAC reference monitoring